Item 8.01 Other Events.
In connection with its partnership with the National Institute for Viral Disease
Control and Prevention, Chinese Centre for Disease Control and Prevention,
Beijing Youfeng International Consulting Co., Ltd and Beijing Guoxin Haixiang
Equity Investment Partnership, Generex Biotechnology Corporation and its
majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively "Generex")
received $2,000,000 on April 22, 2021, from Beijing Youfeng Biological
Technology Co. LTD ("YouFeng") to provide necessary materials to YouFeng for its
IND submissions to the Chinese National Medical Products Administration (China's
equivalent to the US Food & Drug Administration) to obtain approval in China for
Generex's Ii-Key SARS-CoV-2 coronavirus peptide vaccine.
Forward-Looking Statements
Statements in this report may contain certain forward-looking statements. All
statements included concerning activities, events or developments that the
Generex expects, believes or anticipates will or may occur in the future are
forward-looking statements. Actual results could differ materially from the
results discussed in the forward-looking statements. Forward-looking statements
are based on current expectations and projections about future events and
involve known and unknown risks, uncertainties and other factors that may cause
actual results and performance to be materially different from any future
results or performance expressed or implied by forward-looking statements. Known
risks and uncertainties also include those identified from time to time in the
reports filed by Generex with the Securities and Exchange Commission, which
should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or events, and one
should avoid placing undue reliance on such statements. Generex undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise. Generex cannot be sure
when or if it will be permitted by regulatory agencies to undertake additional
clinical trials or to commence any particular phase of clinical trials. Because
of this, statements regarding the expected timing of clinical trials or ultimate
regulatory approval cannot be regarded as actual predictions of when Generex
will obtain regulatory approval for any "phase" of clinical trials or when it
will obtain ultimate regulatory approval by a particular regulatory agency.
Generex claims the protection of the safe harbor for forward-looking statements
that is contained in the Private Securities Litigation Reform Act. Additional
information on these and other risks, uncertainties and factors is included in
the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q,
Current Reports on Form 8- K and other documents filed with the SEC.
2
© Edgar Online, source Glimpses